Insmed Rises on Drug Approval for Debilitating Lung Disease (1)

Insmed Inc. rose after US regulators approved its drug Brinsupri as the first treatment for a debilitating lung condition, ending two centuries of waiting and paving the way for a potential new blockbuster.

The once-daily pill, known chemically as brensocatib, eases bronchiectasis, a chronic inflammatory disease that damages the airways and can make it hard to breathe. Patients struggle to clear mucus from their lungs, which creates a breeding ground for infections and often lands them in the hospital for long periods.

The US Food and Drug Administration approved both doses of the medicine without requirements about patients’ previous disease ...